Cigna Investments Inc. New increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 0.0% during the second quarter, Holdings Channel reports. The fund owned 50,250 shares of the medical instruments supplier’s stock after buying an additional 10 shares during the period. Cigna Investments Inc. New’s holdings in AngioDynamics were worth $815,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ANGO. Dimensional Fund Advisors LP increased its position in shares of AngioDynamics by 0.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,128,777 shares of the medical instruments supplier’s stock valued at $54,285,000 after buying an additional 14,823 shares during the last quarter. Vanguard Group Inc. increased its position in shares of AngioDynamics by 7.4% in the first quarter. Vanguard Group Inc. now owns 1,694,290 shares of the medical instruments supplier’s stock valued at $29,396,000 after buying an additional 116,814 shares during the last quarter. Royce & Associates LP increased its position in shares of AngioDynamics by 18.7% in the first quarter. Royce & Associates LP now owns 810,312 shares of the medical instruments supplier’s stock valued at $14,059,000 after buying an additional 127,764 shares during the last quarter. Peregrine Capital Management LLC bought a new position in shares of AngioDynamics during the second quarter valued at approximately $12,133,000. Finally, Ameriprise Financial Inc. increased its position in shares of AngioDynamics by 22.4% in the first quarter. Ameriprise Financial Inc. now owns 614,721 shares of the medical instruments supplier’s stock valued at $10,666,000 after buying an additional 112,693 shares during the last quarter. 85.84% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics, Inc. (NASDAQ:ANGO) opened at 16.36 on Friday. The stock has a 50 day moving average price of $16.21 and a 200-day moving average price of $16.17. The firm has a market capitalization of $598.45 million, a P/E ratio of 119.42 and a beta of 1.15. AngioDynamics, Inc. has a 52 week low of $14.80 and a 52 week high of $18.18.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The business had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. During the same period last year, the business posted $0.19 earnings per share. AngioDynamics’s quarterly revenue was down 7.0% compared to the same quarter last year. Analysts anticipate that AngioDynamics, Inc. will post $0.67 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Cigna Investments Inc. New Buys 10 Shares of AngioDynamics, Inc. (ANGO)” was published by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/cigna-investments-inc-new-buys-10-shares-of-angiodynamics-inc-ango/1477312.html.

ANGO has been the topic of a number of recent analyst reports. Barclays PLC dropped their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 19th. BidaskClub downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. Cantor Fitzgerald boosted their price objective on AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Finally, Canaccord Genuity reissued a “hold” rating and issued a $17.00 price objective on shares of AngioDynamics in a research note on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $18.50.

In related news, CEO James C. Clemmer acquired 5,000 shares of the stock in a transaction on Friday, July 21st. The stock was acquired at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the completion of the acquisition, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at approximately $1,368,724.57. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO James C. Clemmer acquired 20,000 shares of the stock in a transaction on Thursday, July 20th. The stock was bought at an average price of $15.64 per share, with a total value of $312,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The disclosure for this purchase can be found here. Insiders acquired 25,316 shares of company stock valued at $396,806 over the last 90 days. 1.88% of the stock is currently owned by company insiders.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.